TBPH (Theravance Biopharma) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TBPH Theravance Biopharma Inc TBPH
72 GF Score
Price $16.86
GF Value $18.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Theravance Biopharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Theravance Biopharma's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

TBPH vs ABUS, SANA, ANNX: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Theravance Biopharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theravance Biopharma Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Margin of Safety % (DCF FCF Based) falls into.


TBPH
72GF Score
Theravance Biopharma Inc TBPH
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theravance Biopharma (TBPH) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of $16.86 is trading 9.7% below its estimated GF Value™ of $18.67. GuruFocus considers Theravance Biopharma to be Modestly Undervalued.

Key valuation signals for TBPH:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $18.67 vs. price of $16.86 (9.7% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theravance Biopharma Business Description

Other Exchanges 0TB:Germany
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for TBPH

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.86
Price
$18.67
GF Value